

Kardiale Überwachung von Patienten mit Multipler Sklerose beim Einsatz von Fingolimod

Expertenempfehlung

Surveillance cardiaque des patients souffrant de sclérose en plaques débutant un traitement par fingolimod

Recommandations d'experts

Literatur / Références

1. Cohen JA, Chun J. Mechanisms of Fingolimod's Efficacy and Adverse Effects in Multiple Sclerosis. *Ann Neurol* 2011;69:759–777.
2. Cohen JA, Barkhof F, Comi G, Hartung HP, Khatri BO, Montalban X et al. Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis. *N Engl J Med*. 2010;362(5):402–15.
3. Khatri BO, Barkhof F, Comi G, Hartung HP, Kappos L, Montalban X et al. Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study. *Lancet Neurol* 2011;10: 520–29.
4. Calabresi PA, Goodin D, Jeffery D, Kappos L, Lublin FD, Rammohan K et al. Efficacy and safety of fingolimod versus placebo: Primary outcomes from the phase 3 FREEDOMS II study in patients with relapsing–remitting multiple sclerosis. *ECTRIMS 2012*; Abstract P491.
5. Kappos L, Radue EW, O'Connor P, Polman C, Hohlfeld R, Calabresi P et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. *N Engl J Med* 2010;362(5):387–401.
6. Minneboo A, Jasperse B, Barkhof F, Uitdehaag BM, Knol DL, de Groot V et al. Predicting short-term disability progression in early multiple sclerosis: added value of MRI parameters. *J Neurol Neurosurg Psychiatry* 2008;79(8):917–23.
7. Kappos L, Radue EW, O'Connor P, Polman C, Hohlfeld R, Selmaj K et al. Phase 3 FREEDOMS study extension: Fingolimod (FTY720) efficacy in patients with relapsing–remitting multiple sclerosis receiving continuous or placebo–fingolimod switched therapy for up to 4 years. *Ectrims 2012*, Poster P979.
8. Montalban X, Barkhof F, Comi G, Hartung HP, Kappos L, Khatri B et al. Long-term comparison of fingolimod with interferon beta-1a: results of 4.5–year follow-up from the extension phase III TRANSFORMS study. *Ectrims 2012*, Poster P517.
9. <http://www.novartis.com/newsroom/media-releases/en/2013/1688111.shtml>
10. Fachinformation Gilenya®. Arzneimittel-Kompendium der Schweiz, 2013. Unter <http://www.swissmedicinfo.ch/>
11. O'Connor P, Polman C, Hohlfeld R, Selmaj K, Olsson T, Agoropoulou C et al. Phase 3 FREEDOMS study extension: Long-term safety of fingolimod (FTY720) in relapsing–remitting multiple sclerosis. *Ectrims 2012*; Poster P523.
12. Cohen JA, O'Connor P, Caliolio T, von Rosenstiel P, Zhang-Auberson L, Keil A et al. Long-term safety of fingolimod in relapsing multiple sclerosis: Update to integrated analyses of phase 2 and 3 studies and extension phases. *Ectrims 2012*; Poster P983.
13. <http://www.fda.gov/safety/medwatch/howtoreport/ucm053087.htm>
14. DiMarco JP, O'Connor P, Cohen JA, Reder AT, Zhang-Auberson L, Tang D et al. Fingolimod treatment initiation experience: Cardiac and Holter electrocardiogram findings from three phase 3 studies. *Ectrims 2012*; Poster P530.
15. Kovarik JM, Lu M, Riviere GJ, Barbet I, Maton S, Goldwater DR et al. The effect on heart rate of combining single-dose fingolimod with steady-state atenolol or diltiazem in healthy subjects. *Eur J Clin Pharmacol* 2008;64(5):457–63.
16. Gold R, Kappos L, Palace J, Siever A, Marrosu MG, Gottschalk R et al. Cardiac safety of fingolimod 0.5 mg during the first-dose observation in a 4–month, open-label, multi-centre FIRST study in relapsing multiple sclerosis patients. *ENS 2012*, Poster P347.
17. Espinosa PS, Berger JR. Delayed fingolimod-associated asystole. *Mult Scler* 2011;17:1387–89.
18. Lindsey JW et al. Sudden unexpected death on fingolimod. *Mult Scler* 2012;18(10):1507–8.
19. Faber H, Fischer HJ, Weber F. Prolonged and symptomatic bradycardia following a single dose of fingolimod. *Mult Scler*. 2013;19(1):126–8.
20. <http://www.swissmedic.ch/marktueberwachung/00091/00092/02069/index.html?lang=de>
21. <http://www.swissmedic.ch/marktueberwachung/00091/00092/02299/index.html?lang=de>